<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04314674</url>
  </required_header>
  <id_info>
    <org_study_id>Neuroanesthesia Cerrahpasa</org_study_id>
    <nct_id>NCT04314674</nct_id>
  </id_info>
  <brief_title>Comparison of Hypertonic Saline and Mannitol on Brain Relaxation During Supratentorial Tumors Resection</brief_title>
  <official_title>Comparison of Continuous Infusion of 3% Hypertonic Saline, Bolus of 3% Hypertonic Saline and Mannitol on Brain Relaxation During Supratentorial Tumor Resection: A Prospective, Randomized, Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperosmotic agents are used to decrease intracranial pressure. The aim of the study is to
      compare the effects of continuous 3% hypertonic saline (HS), bolus HS and 20% mannitol on
      intraoperative brain relaxation in patients with raised intracranial pressure during surgery
      for supratentorial tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After obtaining approval from the ethics committee and informed consent, a total of 90
      patients aged 18-70 years, conscious (GCS&gt;13) and American Society of Anesthesiologists (ASA)
      class I-III, who had intracranial shift &gt;0.5 cm or glioblastoma multiforme or metastatic
      tumor and who were scheduled for supratentorial mass resection under elective conditions,
      will be included in the present prospective, randomized, double-blind and placebo-controlled
      study. Patients with heart failure, kidney insufficiency, diabetes insipidus, electrolyte
      imbalance and who are unconscious will be excluded from the study.

      The patients will randomized into 3 groups:

      Group 1: %3 HS bolus 3 mL.kg-1 Group 2: %3 HS infusion 20 ml/h Group 3: %20 mannitol 0,6
      gr.kg-1 After head fixation, all patients will be administered with HS or mannitol (over 20
      minutes). Arterial blood gas (ABG) analysis (Cobas b 221 blood gas analyzer, Roche®, Basel,
      Switzerland) will be made at 30 minute,2,4,6,8. hours. Blood sodium, potassium, chlorine,
      base excess, lactate levels and blood osmolarity will be recorded in each time intervals. The
      brain relaxation scale will be recorded at the time of dura opening.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group 1: %3 HS bolus 3 mL.kg-1 Group 2: %3 HS infusion 20 ml/h Group 3: %20 mannitol 0,6 gr.kg-1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>All the patients, the anesthesiologist who will evaluate the postoperative cranial CT will be blind to study group</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Brain relaxation score</measure>
    <time_frame>1. min before dura closure</time_frame>
    <description>Brain relaxation score 1: Brain is under the dura, 2: Brain is in the dura level, 3:Brain is above the dura, 4: There is no pulsation in the brain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sodium level</measure>
    <time_frame>Baseline and after the drug administration 30. min, 2,4,6,8. hours</time_frame>
    <description>Blood sodium levels obtained from arterial blood gases analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium level</measure>
    <time_frame>Baseline and after the drug administration 30. min, 2,4,6,8. hours</time_frame>
    <description>Blood potassium levels obtained from arterial blood gases analysis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Brain Tumor - Metastatic</condition>
  <condition>Brain Tumor, Adult: Glioblastoma</condition>
  <arm_group>
    <arm_group_label>%3 HS bolus 3 mL.kg-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After the head fixation 3 mL.kg-1 %3 hypertonic saline will be administered over the 20 min intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>%3 HS infusion 20 ml/h</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After the head fixation 3% hypertonic saline at 20 ml/h infusion rate will be administered during the operation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>%20 mannitol 0,6 gr.kg-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After the head fixation %20 mannitol 0,6 gr.kg-1 will be administered over the 20 min intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>%3 HS bolus</intervention_name>
    <description>After head fixation %3 HS bolus 3 ml/kg will be administered</description>
    <arm_group_label>%3 HS bolus 3 mL.kg-1</arm_group_label>
    <other_name>Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>%3 HS infusion 20 ml/h</intervention_name>
    <description>After head fixation %3 HS 20 ml/h infusion will be administered</description>
    <arm_group_label>%3 HS infusion 20 ml/h</arm_group_label>
    <other_name>Group 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20% mannitol</intervention_name>
    <description>After head fixation %20 mannitol 0.6 ml/kg will be administered</description>
    <arm_group_label>%20 mannitol 0,6 gr.kg-1</arm_group_label>
    <other_name>Group 3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective supratentorial tumor resection

          -  Glioblastoma multiforme

          -  Metastatic tumor

          -  Intracranial shift &gt;0.5 cm

          -  GCS&gt;13

        Exclusion Criteria:

          -  Renal failure

          -  Heart failure

          -  Electrolyte imbalance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusuf Tunali</last_name>
    <role>Study Director</role>
    <affiliation>Professor of the department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eren F Akcil</last_name>
    <phone>00905327992399</phone>
    <email>erenfat@yahoo.com</email>
  </overall_contact>
  <reference>
    <citation>Quentin C, Charbonneau S, Moumdjian R, Lallo A, Bouthilier A, Fournier-Gosselin MP, Bojanowski M, Ruel M, Sylvestre MP, Girard F. A comparison of two doses of mannitol on brain relaxation during supratentorial brain tumor craniotomy: a randomized trial. Anesth Analg. 2013 Apr;116(4):862-8. doi: 10.1213/ANE.0b013e318282dc70. Epub 2013 Jan 25.</citation>
    <PMID>23354336</PMID>
  </reference>
  <reference>
    <citation>Dostal P, Dostalova V, Schreiberova J, Tyll T, Habalova J, Cerny V, Rehak S, Cesak T. A comparison of equivolume, equiosmolar solutions of hypertonic saline and mannitol for brain relaxation in patients undergoing elective intracranial tumor surgery: a randomized clinical trial. J Neurosurg Anesthesiol. 2015 Jan;27(1):51-6. doi: 10.1097/ANA.0000000000000091.</citation>
    <PMID>25036870</PMID>
  </reference>
  <reference>
    <citation>Hernández-Palazón J, Fuentes-García D, Doménech-Asensi P, Piqueras-Pérez C, Falcón-Araña L, Burguillos-López S. A comparison of equivolume, equiosmolar solutions of hypertonic saline and mannitol for brain relaxation during elective supratentorial craniotomy. Br J Neurosurg. 2016;30(1):70-5. doi: 10.3109/02688697.2015.1109061. Epub 2015 Nov 16.</citation>
    <PMID>26571037</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 15, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Eren Fatma Akcil</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>hypertonic saline, mannitol, supratentorial brain tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Supratentorial Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

